Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pembrolizumab

(pem-broh-LIH-zoo-mab)
A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1, that have certain mutations (changes) in genes involved in DNA repair, or that have a high number of tumor mutations. Pembrolizumab is used alone or with other drugs to treat certain types of biliary tract cancer (including bile duct cancer and gallbladder cancer), breast cancer, cervical cancer, classic Hodgkin lymphoma, colorectal cancer, endometrial cancer, esophageal cancer, gastroesophageal junction cancer, head and neck squamous cell carcinoma (SCC), hepatocellular carcinoma (a type of liver cancer), malignant pleural mesothelioma, non-small cell lung cancer, primary mediastinal large B-cell lymphoma, renal cell carcinoma (a type of kidney cancer), skin cancer (SCC of the skin, Merkel cell carcinoma, and melanoma), stomach cancer, urothelial carcinoma (a type of bladder or urinary tract cancer), and other solid tumors. It is also being studied in the treatment of other types of cancer. Pembrolizumab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Keytruda.
More Information
Search NCI's Dictionary of Cancer Terms